These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21233022)

  • 1. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.
    Dhodapkar MV; Richter J
    Clin Immunol; 2011 Aug; 140(2):160-6. PubMed ID: 21233022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing CD1d-restricted T cells toward antitumor immunity in humans.
    Neparidze N; Dhodapkar MV
    Ann N Y Acad Sci; 2009 Sep; 1174():61-7. PubMed ID: 19769737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
    Singh AK; Rhost S; Löfbom L; Cardell SL
    Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.
    Rzemieniak SE; Hirschfeld AF; Victor RE; Chilvers MA; Zheng D; van den Elzen P; Turvey SE
    Immunology; 2010 Jun; 130(2):288-95. PubMed ID: 20102408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of natural killer T cells in antitumor immunotherapy.
    Hong C; Park SH
    Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
    Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
    Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d.
    Almeida CF; Smith DGM; Cheng TY; Harpur CM; Batleska E; Nguyen-Robertson CV; Nguyen T; Thelemann T; Reddiex SJJ; Li S; Eckle SBG; Van Rhijn I; Rossjohn J; Uldrich AP; Moody DB; Williams SJ; Pellicci DG; Godfrey DI
    Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34417291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKT and tolerance.
    Diana J; Beaudoin L; Gautron AS; Lehuen A
    Methods Mol Biol; 2011; 677():193-206. PubMed ID: 20941612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human NKT cells express granulysin and exhibit antimycobacterial activity.
    Gansert JL; Kiessler V; Engele M; Wittke F; Röllinghoff M; Krensky AM; Porcelli SA; Modlin RL; Stenger S
    J Immunol; 2003 Mar; 170(6):3154-61. PubMed ID: 12626573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications.
    Papoutselis M; Spanoudakis E
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):358-365. PubMed ID: 32234294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
    Padte NN; Li X; Tsuji M; Vasan S
    Clin Immunol; 2011 Aug; 140(2):142-51. PubMed ID: 21185784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.
    Dhodapkar MV; Geller MD; Chang DH; Shimizu K; Fujii S; Dhodapkar KM; Krasovsky J
    J Exp Med; 2003 Jun; 197(12):1667-76. PubMed ID: 12796469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
    Webb TJ; Bieler JG; Schneck JP; Oelke M
    J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct CD1d docking strategies exhibited by diverse Type II NKT cell receptors.
    Almeida CF; Sundararaj S; Le Nours J; Praveena T; Cao B; Burugupalli S; Smith DGM; Patel O; Brigl M; Pellicci DG; Williams SJ; Uldrich AP; Godfrey DI; Rossjohn J
    Nat Commun; 2019 Nov; 10(1):5242. PubMed ID: 31748533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
    Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
    J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
    Van Kaer L; Wu L; Parekh VV
    Immunology; 2015 Sep; 146(1):1-10. PubMed ID: 26032048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.
    Fujii S; Shimizu K; Steinman RM; Dhodapkar MV
    J Immunol Methods; 2003 Jan; 272(1-2):147-59. PubMed ID: 12505720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.
    Nur H; Fostier K; Aspeslagh S; Renmans W; Bertrand E; Leleu X; Favreau M; Breckpot K; Schots R; De Waele M; Van Valckenborgh E; De Bruyne E; Facon T; Elewaut D; Vanderkerken K; Menu E
    PLoS One; 2013; 8(5):e65075. PubMed ID: 23741460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
    Gerth E; Mattner J
    Front Immunol; 2019; 10():1449. PubMed ID: 31293596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.